Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous tumor membrane vesicles vaccine

An autologous personalized tumor vaccine composed of tumor membrane vesicles (TMV) derived from the patient's own tumor cells, with potential immunostimulating and antineoplastic activities. Upon administration of the autologous TMV vaccine, the antigenic proteins in the vaccine are presented to the immune system and activate antigen-presenting cells (APCs). This may stimulate the immune system to mount cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte responses against the patient's tumor cells that express these same antigens, thereby killing the tumor cells. TCMVs contain tumor proteins and surface antigens that can stimulate an immune response.
Synonym:autologous TDMV-derived vaccine
autologous TMV vaccine
autologous TMV-based vaccine
autologous tumor-derived membrane vesicles vaccine
Search NCI's Drug Dictionary